EMA Authorised: Briumvi (ublituximab) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The European Medicines Agency authorised Briumvi (ublituximab) for multiple sclerosis, including relapsing-remitting disease, with Neuraxpharm Pharmaceuticals S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BRIUMVI (ublituximab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 04/09/2025